Electroconvulsive Therapy (ECT): How It Works, What to Expect, and What the Evidence Shows

Electroconvulsive therapy (ECT) is a medical procedure in which carefully controlled electrical currents are passed through the brain to intentionally induce a brief, generalized seizure. Performed under general anesthesia with muscle relaxants, modern ECT bears little resemblance to the unmodified procedures depicted in popular media. It is one of the oldest and most extensively studied treatments in psychiatry, first introduced in 1938 and refined dramatically over the following decades.

ECT is typically reserved for severe psychiatric conditions that have not responded adequately to medication and psychotherapy — a situation clinicians call treatment-resistant illness. It is also used in psychiatric emergencies where rapid symptom relief is critical, such as acute suicidality, catatonia, or psychotic states with dangerous agitation or refusal to eat and drink.

Despite decades of stigma fueled by its early, unrefined use, ECT is now considered one of the most effective treatments available in all of psychiatry. The American Psychiatric Association (APA), the National Institute of Mental Health (NIMH), and the Royal College of Psychiatrists all recognize ECT as a safe, evidence-based intervention when appropriately indicated.

The precise mechanism by which ECT produces its therapeutic effects is not fully understood, but decades of neurobiological research have identified several important pathways. Understanding what happens in the brain during and after ECT helps demystify the treatment and clarify why it can be so effective.

Seizure induction and neurotransmitter modulation: The therapeutic benefit of ECT is believed to depend on the generalized seizure itself — not simply the electrical stimulation. The seizure triggers a massive release of neurotransmitters including serotonin, dopamine, norepinephrine, and gamma-aminobutyric acid (GABA). This surge appears to "reset" disrupted signaling patterns in brain circuits involved in mood regulation, motivation, and cognition.

Neuroplasticity and neurogenesis: Research using neuroimaging has shown that ECT increases the volume of the hippocampus — a brain structure critical for memory and emotional regulation that is often reduced in volume in people with severe depression. ECT also increases levels of brain-derived neurotrophic factor (BDNF), a protein that supports the growth, survival, and differentiation of neurons. These findings suggest ECT promotes neuroplasticity — the brain's ability to form new neural connections and repair damaged ones.

Neuroendocrine effects: ECT influences the hypothalamic-pituitary-adrenal (HPA) axis, which governs the body's stress response. Chronic hyperactivation of this axis is a well-documented feature of severe depression. ECT appears to help normalize HPA axis functioning, reducing cortisol levels and dampening the overactive stress response.

Connectivity changes: Functional MRI studies have demonstrated that ECT alters connectivity within key brain networks, particularly the default mode network (associated with rumination and self-referential thinking) and the cognitive control network. These changes correlate with clinical improvement in depressive symptoms.

ECT is not a first-line treatment for most psychiatric conditions. It is typically considered when other interventions have failed or when the clinical situation demands rapid response. The following conditions have the strongest evidence base for ECT:

• Major Depressive Disorder (MDD), particularly treatment-resistant depression: This is the most common indication for ECT. Research consistently shows that ECT produces remission in approximately 50–70% of patients with treatment-resistant depression — a rate substantially higher than switching or augmenting antidepressant medications. ECT is particularly effective for depression with psychotic features, where remission rates can exceed 80%.
• Bipolar Disorder — depressive and manic episodes: ECT is effective for both severe bipolar depression and acute mania that has not responded to pharmacotherapy. It is one of the few treatments with robust evidence for both poles of the illness.
• Catatonia: Catatonia is a syndrome of motor, behavioral, and cognitive abnormalities that can occur in the context of mood disorders, schizophrenia, autism spectrum disorder, and medical conditions. ECT is considered the gold-standard treatment for catatonia that does not respond to benzodiazepines, with response rates of 80–100% in published case series.
• Schizophrenia and schizoaffective disorder: ECT is used as an augmentation strategy in treatment-resistant schizophrenia, particularly when prominent mood symptoms, catatonic features, or acute suicidality are present. It is generally used alongside antipsychotic medication rather than as a standalone treatment.
• Acute suicidality: Because ECT can produce rapid improvement in suicidal ideation — often within days, compared to weeks for most medications — it is an important intervention in psychiatric emergencies where the risk of self-harm is imminent.
• Neuroleptic malignant syndrome (NMS): This rare but life-threatening reaction to antipsychotic medications can be treated with ECT when other interventions are insufficient.

Emerging research has explored ECT's potential role in treatment-resistant obsessive-compulsive disorder, Parkinson's disease with co-occurring depression, and certain forms of epilepsy, though evidence in these areas remains limited and is an active area of investigation.

For individuals considering ECT, understanding the practical details of the procedure — from preparation through recovery — can significantly reduce anxiety about the process.

Pre-treatment evaluation: Before ECT begins, a thorough medical and psychiatric evaluation is conducted. This typically includes a physical examination, blood work, an electrocardiogram (ECG), and sometimes brain imaging. A psychiatrist will review the patient's medication history, discuss risks and benefits in detail, and obtain informed consent. An anesthesiologist will assess fitness for general anesthesia.

The procedure itself: ECT is performed in a designated treatment suite, often within a hospital or specialized outpatient clinic. The entire session — from preparation to recovery — typically takes about one to two hours, though the procedure itself lasts only a few minutes.

• The patient is placed on a treatment table and connected to monitoring equipment (ECG, blood pressure cuff, pulse oximeter, electroencephalogram or EEG).
• An intravenous (IV) line is established, through which a short-acting general anesthetic (commonly methohexital or propofol) and a muscle relaxant (succinylcholine) are administered.
• Once the patient is asleep and muscles are relaxed, a bite block is placed in the mouth to protect the teeth and tongue.
• Electrodes are placed on the scalp — either on both sides of the head (bilateral placement) or on the right side only (right unilateral placement). Right unilateral placement is associated with fewer cognitive side effects and is often preferred as a starting approach, while bilateral placement is sometimes used when a more robust response is needed.
• A precisely calibrated electrical stimulus is delivered, lasting a fraction of a second. The resulting seizure typically lasts 25–60 seconds and is monitored via EEG.
• Because of the muscle relaxant, the physical manifestations of the seizure are minimal — often just a slight rhythmic movement of the feet or hands.

After the procedure: Patients wake from anesthesia within minutes and are monitored in a recovery area for 30–60 minutes. Common immediate effects include temporary confusion, mild headache, nausea, and muscle aches. Most patients can return home the same day (outpatient ECT) with a companion, though some receive ECT during an inpatient psychiatric admission.

Treatment schedule: An acute course of ECT typically involves 6–12 sessions administered two to three times per week over several weeks. Some patients experience significant improvement after just a few sessions, while others require the full course. After the acute phase, maintenance ECT — sessions administered at gradually increasing intervals (weekly, then biweekly, then monthly) — is often recommended to prevent relapse, particularly for patients whose illness has been highly recurrent or difficult to treat.

ECT has one of the strongest evidence bases of any treatment in psychiatry, supported by decades of randomized controlled trials, systematic reviews, and meta-analyses.

Depression: A landmark meta-analysis published in The Lancet found that ECT was significantly more effective than pharmacotherapy for severe depression, with remission rates of approximately 50–70% compared to 20–30% for medication switches or augmentation in treatment-resistant cases. The UK ECT Review Group's Cochrane analysis confirmed that real ECT is substantially more effective than sham (placebo) ECT, establishing that its benefits are not attributable to placebo effects or the anesthesia alone.

Speed of response: One of ECT's most important clinical advantages is its rapid onset of action. While antidepressant medications typically require 4–8 weeks to reach full effect, ECT often produces measurable improvement within the first week of treatment. This makes it uniquely valuable in acute psychiatric emergencies.

Psychotic depression: ECT is particularly effective for major depression with psychotic features — a severe subtype characterized by delusions or hallucinations in addition to depressive symptoms. Research consistently demonstrates remission rates of 80–90% for this condition, making ECT the most effective known treatment.

Relapse prevention: A significant limitation of ECT is the high relapse rate following a successful acute course if no continuation treatment is provided. Studies indicate that without maintenance treatment, approximately 50–80% of patients relapse within six months. However, continuation ECT combined with pharmacotherapy significantly reduces this risk. A study published in the Journal of Clinical Psychiatry found that the combination of maintenance ECT and medication was superior to medication alone in preventing relapse.

Comparative effectiveness: Head-to-head comparisons with newer treatments like ketamine/esketamine are an active area of research. Preliminary findings suggest that both ECT and ketamine produce rapid antidepressant effects, but ECT may produce more durable remissions. A 2023 randomized trial published in the New England Journal of Medicine found ketamine to be noninferior to ECT for treatment-resistant depression over a short-term period, though longer-term outcomes continue to be studied.

Like all medical procedures, ECT carries risks and side effects that must be weighed against its substantial benefits. Informed consent requires a thorough discussion of these issues.

Cognitive side effects: This is the most significant concern associated with ECT and the most common reason patients express reluctance about the treatment.

• Acute confusion (postictal delirium): Brief disorientation and confusion immediately following each treatment is common and typically resolves within 30–60 minutes.
• Anterograde amnesia: Difficulty forming new memories during the course of treatment is common but usually temporary, resolving within weeks of completing the acute course.
• Retrograde amnesia: Loss of memories formed before or during the ECT course is the most concerning cognitive effect. This most often affects memories from the weeks or months surrounding treatment, though some patients report gaps extending further back. For most patients, the majority of these memories return over time. However, a subset of patients report persistent gaps in autobiographical memory — the ability to recall specific personal life events — that may not fully resolve.

Important advances have significantly reduced cognitive side effects. Right unilateral electrode placement with ultrabrief pulse width stimulation produces substantially fewer memory problems than bilateral, brief-pulse ECT — the older standard — while maintaining strong efficacy, particularly when the electrical dose is adequately titrated above the seizure threshold.

Physical side effects: Headache (reported by approximately 45% of patients), nausea, muscle soreness, and jaw pain are common but usually mild and manageable with standard medications. These effects are transient and diminish as the treatment course progresses.

Medical risks: The risks associated with general anesthesia apply to ECT as they do to any procedure requiring anesthesia, though the total anesthesia time for each ECT session is very brief (typically under 10 minutes). Cardiac arrhythmias can occur during or immediately after the seizure, which is why continuous cardiac monitoring is standard. The mortality rate associated with ECT is estimated at approximately 2–4 per 100,000 treatments, which is comparable to the risk of general anesthesia for minor surgical procedures and substantially lower than the mortality risk of untreated severe depression.

Limitations:

• ECT requires repeated sessions and is time-intensive, particularly for patients who must travel to a treatment center.
• High relapse rates necessitate ongoing maintenance treatment.
• Access is limited by geography, cost, and the availability of trained providers.
• Stigma remains a significant barrier, with many patients and even some clinicians holding outdated or inaccurate views of the procedure.
• ECT does not work for everyone — approximately 30–50% of patients with treatment-resistant depression do not achieve remission with ECT.

ECT is typically available at academic medical centers, large hospital systems, and specialized psychiatric facilities. Finding a qualified provider involves several steps:

• Start with your psychiatrist or primary care provider: A referral from a treating clinician is the most common pathway to ECT. Most ECT services require a referral and pre-treatment evaluation.
• Contact university-affiliated hospitals: Academic medical centers with departments of psychiatry are the most likely to offer ECT and often have dedicated ECT programs staffed by specialists with extensive experience.
• Search hospital and health system directories: Many hospital websites list ECT among their psychiatric services. Searching for "ECT program" along with your city or region is a practical starting point.
• National and regional resources: Organizations such as the International Society for ECT and Neurostimulation (ISEN) maintain directories of providers and can assist in locating treatment centers.
• Questions to ask a prospective provider: How many ECT procedures does the facility perform annually? What electrode placements and pulse widths are used? What is the team's approach to minimizing cognitive side effects? What maintenance and follow-up protocols are offered?

It is important to seek treatment from providers who perform ECT regularly and follow current best practices, including the use of modern stimulus parameters (ultrabrief pulse, right unilateral placement as a first approach), individualized dose titration, and integrated post-ECT care planning.

Cost and accessibility remain significant barriers to ECT for many patients, despite its strong evidence base.

Cost: The cost of a single ECT session in the United States varies widely, typically ranging from $800 to $2,500 per session depending on the facility, geographic region, and whether it is performed on an inpatient or outpatient basis. A full acute course of 6–12 sessions can therefore cost $5,000 to $25,000 or more before insurance. Maintenance ECT adds ongoing costs, though sessions are less frequent.

Insurance coverage: Most major health insurance plans, including Medicare and Medicaid, cover ECT when it is deemed medically necessary. However, prior authorization requirements, varying copay structures, and limitations on the number of covered sessions can create hurdles. Patients should work with their treatment team and insurance provider to understand their specific coverage and advocate for authorization when needed.

Geographic accessibility: ECT availability is concentrated in urban areas and academic medical centers. Rural communities and smaller cities often lack ECT programs entirely, forcing patients to travel significant distances — sometimes hours each way — for treatment that may be required two to three times per week. This geographic disparity disproportionately affects patients in underserved communities.

Stigma as a barrier: Beyond financial and logistical concerns, the persistent stigma surrounding ECT deters some patients from pursuing it even when clinically indicated. Educational initiatives aimed at both the public and healthcare professionals are critical to addressing this barrier. Hearing from other patients who have undergone ECT — through support groups or patient advocacy organizations — can be particularly helpful.

Time and logistics: Because patients receive general anesthesia, they cannot drive themselves to or from treatments. Each session requires a companion for transportation, and the recovery period means a half-day commitment per session. For working individuals, the time burden of an acute ECT course can be substantial, though many find it comparable to or less than the time lost to the disabling symptoms of untreated severe depression.

For individuals who are unable or unwilling to pursue ECT, or for whom ECT has not been effective, several alternative treatments exist for treatment-resistant psychiatric conditions:

• Ketamine and esketamine: Ketamine, an NMDA receptor antagonist, has emerged as a rapid-acting treatment for treatment-resistant depression. Esketamine (Spravato), a nasal spray formulation of the S-enantiomer of ketamine, is FDA-approved for treatment-resistant depression and major depression with acute suicidal ideation. These treatments produce rapid antidepressant effects (often within hours to days) but require ongoing maintenance sessions and carry their own risks, including dissociation, elevated blood pressure, and potential for misuse.
• Transcranial magnetic stimulation (TMS): TMS uses magnetic pulses to stimulate specific brain regions, most commonly the left dorsolateral prefrontal cortex. It is FDA-cleared for treatment-resistant depression, OCD, and smoking cessation. TMS is noninvasive, does not require anesthesia, and has a favorable side-effect profile. However, its efficacy for severe depression is generally considered lower than ECT's — remission rates for standard TMS protocols are approximately 20–35%. Newer accelerated TMS protocols (such as the Stanford Neuromodulation Therapy, or SNT protocol) have shown more promising results in early research.
• Vagus nerve stimulation (VNS): VNS involves surgical implantation of a device that delivers electrical pulses to the vagus nerve. It is FDA-approved for treatment-resistant depression but has a slow onset of action (months) and modest response rates. It is generally considered only after multiple other treatments have failed.
• Medication optimization: Before pursuing neuromodulation therapies, thorough pharmacotherapy optimization — including adequate dose titration, sufficient trial duration, augmentation strategies (such as lithium or atypical antipsychotic augmentation), and combination antidepressant regimens — should be explored under the guidance of a psychiatrist experienced in treatment-resistant conditions.
• Psychotherapy: While psychotherapy alone is typically insufficient for the severe, treatment-resistant conditions that warrant ECT consideration, evidence-based psychotherapies such as cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and interpersonal therapy (IPT) remain important components of a comprehensive treatment plan and can enhance and sustain the gains achieved through ECT or other somatic treatments.
• Psilocybin-assisted therapy: Psilocybin, a psychedelic compound, has shown promising results for treatment-resistant depression in phase II clinical trials conducted at institutions such as Johns Hopkins University and Imperial College London. However, it is not yet FDA-approved for any psychiatric indication as of early 2025, and its use outside of clinical trials remains largely restricted.

The choice among these options depends on the severity and nature of the condition, prior treatment history, patient preferences, medical comorbidities, and practical considerations such as cost and access. A collaborative discussion between patient and psychiatrist is essential in determining the most appropriate treatment path.

If you or someone you know is experiencing severe depression, suicidal thoughts, catatonia, or psychiatric symptoms that have not responded to standard medications and therapy, it is important to seek evaluation from a psychiatrist — particularly one with expertise in treatment-resistant conditions or neuromodulation therapies.

ECT may be worth discussing with your provider if:

• You have tried multiple antidepressant medications at adequate doses and durations without sufficient relief
• Your symptoms are severe enough to significantly impair daily functioning, self-care, or safety
• You are experiencing psychotic symptoms in the context of a mood disorder
• You have catatonic features that are not responding to benzodiazepines
• You are in a psychiatric crisis involving imminent risk of self-harm
• You are pregnant and experiencing severe psychiatric illness where medication options are more limited

ECT is a decision made collaboratively between patients, their families, and their treatment team. Seeking a second opinion from an ECT specialist — even if your current provider has not raised it as an option — is always appropriate if you believe your treatment-resistant symptoms warrant a broader discussion of available interventions.

If you are in immediate danger or experiencing a psychiatric emergency, call 988 (Suicide and Crisis Lifeline), go to your nearest emergency department, or call 911.